Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

e the long-term safety of pirfenidone in patients with IPF. ITMN-191 (R7227): -- In November 2008, Roche, InterMune and Pharmasset, Inc. initiated the first all-oral combination study of direct anti-virals in the absence of interferon or ribavirin, known as the INFORM-1 study. That study has completed the first dose cohort. -- On January 12, 2009, InterMune announced top-line results from a 14-day, Phase 1b study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). - After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts in the study, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. - Reductions in HCV RNA occurred rapidly and there was no evidence of viral rebound during ITMN-191 treatment in any cohort. - ITMN-191 was generally safe and well tolerated in the study. There were no serious adverse events or Grade 4 adverse events (AEs) during treatment with ITMN-191. AEs reported during study treatment (ITMN-191 or placebo) were predominantly mild to moderate in severity, typically consistent with the AE profile of standard of care (SOC), and none led to treatment discontinuation. Financial: -- On February 19, 2009, InterMune completed a follow-on public offering of 4,025,000 shares of common stock, including the underwriters' over-allotment, at an offer price of $16.35 per share. Net proceeds to InterMune were approximately $63.5 million after deduction of underwriting fees and other related expenses. -- The Medicines Company announced on February 25, 2009, that it had completed its tender offer for all of the outstanding shares of Targanta Therapeutics Co
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... (PRWEB) March 02, 2015 The ... ReachMD announced today the launch of Genetically ... educate healthcare professionals on the application of human genetics ... series features peer-to-peer interviews conducted during the ASHG 2014 ... ,     Translational Genomics and Health Outcomes Research: What's Ready ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 In the ... industry has experienced robust growth. The industry, which ... industrial materials, energy resources and other goods, has grown ... government regulation. As a result, IBISWorld forecasts that industry ... to reach $946.8 million over the five-year period, including ...
(Date:3/2/2015)... , March 2, 2015 Analyzing ... experts have identified a new syndrome, shedding light ... research also provides important information to help caregivers ... eventually treating it. "This syndrome illuminates ... sort of master switch that controls many other ...
(Date:3/2/2015)... and VANCOUVER, British Columbia ... ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage ... based therapies, today announced that Craig Schneider ... overview during a live webcast at VirtualInvestorConferences.com. ... LINK:   http://VirtualInvestorConferences.com > click the red ...
Breaking Biology Technology:American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 3Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 2New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 3New Genetic Syndrome Found, Arising from Errors in 'Master Switch' During Early Development 4InMed Pharmaceuticals to Present Investor Webcast March 5 2
... Pharsight,Corporation (Nasdaq: PHST ), a leading provider of ... announced today that it will be presenting at B. ... April 2, 2008 at the Palms Las,Vegas. Shawn O,Connor, ... and CFO, will be presenting on April 2nd,at 1:30 ...
... 26, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ),the global specialty biopharmaceutical company, announces the ... plc,("Shares") in connection with the Shire Long Term Incentive Plan ("LTIP")., In accordance ... ... of Shares ...
... the leading provider of,ion channel testing services for ... conference the company,s expanding,line of ion channel services ... need to identify the most promising compounds,and eliminate ... invest millions in,the drug-development process. The 14th Annual ...
Cached Biology Technology:Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Shire plc: Long Term Incentive Plan 2ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104 2ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104 3
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E - ... authentication solutions, today announced it will showcase its EyeLock ID ... by the Department of Energy,s Oak Ridge National Laboratory ... Show . EyeLock,s iris identity authentication technology is being used ...
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... , January 22, 2015 , ... year  The European Patent Office to present a video ... British nominations to be featured: Christofer Toumazou and ... former finalists and winners of the Award   Starting ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... 27 January, 2010 - A recent special edition of the ... the impact of Hurricane Katrina and an overview of the ... Hurricane Katrina was the most destructive natural disaster in U.S. ... storm surge affected the greatest area, nearly 93,000 square miles. ...
... warming may impair the ability of ecosystems to ... and carbon sequestrationsays the nation,s largest organization of ... Ecological Society of America (ESA) outlines strategies that ... to mitigate and adapt to climate change. ...
... This release is available in Spanish . ... minority groups receive worse health care in the treatment of ... developed countries. This conclusion emerges from a research conducted at ... bibliographic review worldwide to date on health care of this ...
Cached Biology News:A forensic analysis of Hurricane Katrina's impact: methods and findings 2Managing ecosystems in a changing climate 2Managing ecosystems in a changing climate 3Poorer diabetics receive worse care than other in countries with universal health coverage 2Poorer diabetics receive worse care than other in countries with universal health coverage 3
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
This antibody detects cdc42 on SDS-PAGE immunoblots....
Biology Products: